What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review by Mc Ardle, Ríona et al.
Northumbria Research Link
Citation:  Mc  Ardle,  Ríona,  Morris,  Rosie,  Wilson,  Joanna,  Galna,  Brook,  Thomas,  Alan  J.  and 
Rochester,  Lynn  (2017)  What  Can  Quantitative  Gait  Analysis  Tell  Us  about  Dementia  and  Its 
Subtypes? A Structured Review. Journal of Alzheimer's Disease, 60 (4). pp. 1295-1312. ISSN 1387-
2877 
Published by: IOS Press
URL: https://doi.org/10.3233/jad-170541 <https://doi.org/10.3233/jad-170541>
This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/42488/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to access 
the University’s research output. Copyright © and moral rights for items on NRL are retained by the 
individual author(s) and/or other copyright owners.  Single copies of full items can be reproduced, 
displayed or performed, and given to third parties in any format or medium for personal research or 
study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, 
title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata 
page. The content must not be changed in any way. Full items must not be sold commercially in any  
format or medium without formal permission of the copyright holder.  The full policy is available online: 
http://nrl.northumbria.ac.uk/pol  i cies.html  
This  document  may differ  from the  final,  published version of  the research  and has been made 
available online in accordance with publisher policies. To read and/or cite from the published version 
of the research, please visit the publisher’s website (a subscription may be required.)
                        

Gait analysis in dementia subtypes 
 
1 
 
 
 
 
 
 
 
What can quantitative gait analysis tell us about dementia and its subtypes? A 
structured review 
 
Ríona Mc Ardle a, Rosie Morris ab, Joanna Wilson a, Brook Galna ac, Alan J. Thomas a & 
Lynn Rochester ab 
a Institute of Neuroscience, Newcastle University Institute of Ageing, Newcastle Upon Tyne, 
UK b Newcastle Upon Tyne Hospital NHS Foundation Trust, UK c School of Biomedical 
Sciences, Newcastle University, UK  
Running heading: Gait analysis in dementia subtypes 
Correspondence: Lynn Rochester, Clinical Ageing Research Unit, Centre for Ageing and 
Vitality, Newcastle University, Nunsmoor Road, NE4 5PL. Email: lynn.rochester@ncl.ac.uk 
Phone: 01912081291 
 
 
Gait analysis in dementia subtypes 
 
2 
 
 
Abstract 
Distinguishing dementia subtypes can be difficult due to similarities in clinical presentation. 
There is increasing interest in discrete gait characteristics as markers to aid diagnostic 
algorithms in dementia. This structured review explores the differences in quantitative gait 
characteristics between dementia and healthy controls, and between four dementia subtypes 
under single-task conditions: Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) 
and Parkinson’s disease dementia (PDD) and vascular dementia (VaD). Twenty-six papers 
out of an initial 5,211 were reviewed and interpreted using a validated model of gait. 
Dementia was associated with gait characteristics grouped by slower pace, impaired rhythm 
and increased variability compared to normal aging.  Only four studies compared two or more 
dementia subtypes. People with AD are less impaired in pace, rhythm and variability domains 
of gait compared to non-AD dementias. Results demonstrate the potential of gait as a clinical 
marker to discriminate between dementia subtypes. Larger studies using a more 
comprehensive battery of gait characteristics and better characterized dementia sub-types are 
required.    
 
Keywords: Alzheimer’s disease, Lewy body disease, biomarker, cognition, diagnosis, 
cognitive impairment 
Gait analysis in dementia subtypes 
 
3 
 
Introduction 
Dementia is a growing global issue with 46.8 million people affected worldwide and 
numbers predicted to rise to 131.5 million by 2050 [1]. Dementia is identified by multiple 
cognitive impairments, which limit everyday functioning. It occurs predominantly in older 
adults and can be categorised into different subtypes. Alzheimer’s Disease (AD) is the most 
common subtype, followed by Lewy body dementia (LBD) and vascular dementia (VaD) [2]. 
Alzheimer’s disease is characterised by gradual onset of memory impairment and is associated 
with neurofibrillary tangles and amyloid beta plaques contributing to neurodegeneration, 
particularly focal to the hippocampal region. Dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD) share symptomology and pathology; they have common 
key symptoms such as parkinsonism, cognitive fluctuations, visual hallucinations and REM 
sleep behaviour disorder, and are associated with Lewy body formation in the brainstem, limbic 
and neocortical areas [3, 4]. Together, these dementia subtypes are referred to as Lewy body 
dementia (LBD). LBD often has concurrent AD pathology, which alters clinical presentation. 
Vascular dementia is heterogeneous in nature and therefore cognitive changes vary greatly [5]. 
The most common findings are subcortical infarcts and white matter ischemia damaging 
frontostriatal circuits, leading to impaired attention, information processing and executive 
function.  
Misdiagnosis of dementia subtypes is problematic in AD and DLB; it is reported that 
34-65% of cases are misdiagnosed [6], due to similarities in cognitive presentation and 
pathology. Some dementia cases, such as AD with subcortical infarcts, have mixed pathology 
which can further hinder accurate diagnosis. Often the need to distinguish subtypes is 
disregarded, as it is not thought to influence care. However, accurate diagnosis of DLB subtype 
is important to prevent mistaking cognitive  fluctuations, key characteristics of DLB, as 
delirium; prevent inappropriate use of antipsychotics; and to facilitate early identification and 
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treatment of motor symptoms, dysautonomia, falls and other characteristic non-psychiatric 
symptoms [7]. Subtypes also have different prognoses, with DLB associated with more rapid 
decline and entering nursing care earlier [8]. The advent of disease modifying treatments will 
also necessitate subtype identification and dementia stratification for the optimal use of such 
therapies. 
Diagnostic markers for dementia, such as cerebrospinal fluid, blood samples, brain 
pathology and cognitive markers, are being investigated to distinguish dementia subtypes and 
improve accuracy of current clinical diagnoses [9]. More recently, gait (and its discrete 
characteristics) have been proposed as potential clinical biomarkers for dementia [10]. Gait is 
a complex skill requiring involvement from widespread brain regions (including those related 
to different cognitive functions, such as the frontal cortex and hippocampus). Changes in brain 
function can therefore lead to subtle changes in distinct gait characteristics, explaining why its 
features may be useful.  Studies show a robust association between gait and cognitive function 
[11], and gait impairments precede and predict cognitive impairment and dementia [10, 12]. 
Therefore, evidence suggests quantitative gait analysis as a plausible diagnostic marker for 
early diagnosis of dementia. However, recent reviews have not addressed the role of gait to 
differentiate between dementia subtypes. 
  In consideration of this, the aims of this review are to establish quantitatively assessed 
gait differences between dementia and non-cognitively impaired older adults, review evidence 
for distinct gait profiles across dementia subtypes and identify recommendations for future 
research. This review will focus on the most common subtypes of dementia: AD, VaD and LBD 
(referring to DLB and PDD). This review will focus solely on single-task gait analysis as dual-
task protocols (which involve walking while engaging in another task) vary widely in both 
methodology and type of secondary task (i.e. tests to assess different cognitive domains or 
manual function). Different tasks may produce different gait impairments and is therefore a 
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subject for further detailed investigation beyond the scope of this review. Assessing differences 
in gait impairment during single-task walking is clinically useful, as it is a simple task to carry 
out and easy to understand – an important consideration for populations with cognitive 
impairment.  For the purposes of this review we will adopt a model of gait (Figure 1) Lord, et 
al. [13]  as a framework to provide structure to the synthesis of  literature and aid interpretation 
of data. We hypothesize that gait will be more impaired across multiple domains in dementia 
compared to controls, and that LBD and VaD will have reduced pace and increased variability 
when walking compared to AD, whereas AD will have more pronounced impairments in 
temporal characteristics of gait. Characteristics relating to reduced pace and increased 
variability are associated with impaired attention and executive function, whilst temporal 
characteristics of gait have been linked to memory [12]. 
Methods 
Search Strategy 
Six databases were used for the search: Scopus, Embase, Web of Science, Psych Articles, 
Medline and Psychinfo. Key terms for the search strategy are detailed in Figure 2. The search 
was limited to papers published from 1946 to October 2016. Other eligible papers brought to 
the reviewers’ attention were also considered. Articles were included if they: i) included at least 
one dementia subtype and control/other clinical cohort (i.e. Parkinson’s disease; PD) or two 
dementia subtypes or at least one dementia subtype at different stages of disease severity; ii) 
included quantitative gait characteristics, obtained from electronic gait analysis, wearable 
technology, motion capture analysis or other suitable means; iii) were original articles; and iv) 
were written in English. Where an article included another clinical cohort (e.g. Parkinson’s 
disease or mild cognitive impairment) or other clinical characteristics (e.g. urinary symptoms), 
only the data relating to dementia and gait was reviewed.  
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Data Extraction 
One reviewer (R.M.A.) screened the titles from the initial search and two reviewers (R.M.A. 
and B.G.) independently screened the abstracts to identify potential articles. Full-text articles 
were retrieved when reviewers could not determine the eligibility of the study from the title and 
abstract. All full-length articles were reviewed by three reviewers (R.M.A, R.M and J.W).  
Data were extracted from eligible articles. The key characteristics of interest were: (i) 
dementia subtypes included, (ii) gait parameters assessed, (iii) method of gait analysis, (iv) 
main findings of the study with respect to gait. A quality assessment was conducted separately 
by two reviewers (R.M.A and J.W) and overall quality scores were determined for each study 
(see Supplementary Table 1).  
Interpretation of data 
Due to the wide and varying range of gait characteristics, several groups have proposed 
models of gait that categorize gait characteristics by domain using data reduction techniques 
[12, 14-16]. Although comparable, there is no standardized model - different models 
emphasize different characteristics and domains. The model chosen for this review was 
validated in older adults and PD (see Figure 1 for more details).  Gait characteristics across 
studies were broadly mapped onto five core domains (Figure 1; hypothesized to represent 
different neural networks involved in locomotor control) in order to structure data 
presentation and interpretation of results for within this review [11]. 
< Insert Figure 1 > 
Gait analysis in dementia subtypes 
 
7 
 
Results 
Search Yield 
The search strategy generated 11,515 papers after exclusion criteria were applied. After 
removing duplicates, 5211 papers remained from the search (see Figure 2). The initial title 
search yielded 376 papers with an abstract screening leaving 55 papers eligible for data 
extraction. Fourteen studies were excluded as they did not specify the subtype of dementia 
(n=10), were not relevant to the review (n=3) or had previously reported results in a paper 
included in the review (n=1). Data were extracted from 42 papers. After data extraction, a 
further 16 papers were removed as they only reported timed gait speed or used functional 
tasks which required additional tasks, such as the Timed Up and Go test. All papers were 
published between 1983 and 2016.  
Out of the remaining 26 articles, the majority of studies investigated AD (n=25; 96%), 
followed by DLB (n=2; 8%), Parkinson’s disease dementia (PDD; n=2; 8%), Lewy body 
dementia (LBD; n=1; 4%), VaD (n=1; 4%) and unspecified non-AD dementia (n=1; 4%). 
Two studies used Parkinson’s disease (PD) for comparison, four used mild cognitive 
impairment (MCI) and 21 used older adult control groups.  
< Insert Figure 2 > 
Measurement of gait in dementia 
Table 1 details the specific characteristics and findings for each of the reviewed papers. 
Quantitative gait analysis included the use of gait walkway systems [17-25], accelerometers 
[26-30], motion capture analysis systems [31-35], pressurized foot-sensors [19, 36-39] and 
combinations of these and other methods such as forceplates [40] and digital cameras [41]. 
One study did not define the instruments they used [42].  
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To examine the wide range of reported gait parameters, all gait characteristics were mapped 
to one of the five domains of gait Lord, et al. [16]. Commonly described gait parameters have 
been described in Supplementary Table 2. All 26 papers investigated pace [17-42], 18 studies 
described characteristics relating to rhythm [18-20, 23-27, 29, 30, 32-35, 38, 39, 41], 13 studies 
reported gait variability [17, 19, 24-29, 31-33, 35, 39], two studies described characteristics of 
gait asymmetry [26, 27] and nine reported parameters relating to postural control [17-20, 25, 
33, 34, 39, 40, 42]. 
< Insert Table 1 > 
Gait impairments in Alzheimer’s Disease 
25 studies assessed gait in AD [17-24, 26-36, 38-42]; 21 of these studies compared AD 
to controls [17-20, 22-30, 32-36, 38, 40, 42], four studies compared AD to other dementia 
subtypes [18, 25, 39, 42], four compared AD to MCI [22, 26-28] and four studies compared 
AD severity levels [21, 31, 36, 41]. 
In AD, all 25 studies assessed characteristics of pace, such as step velocity, step 
length, step, stance and swing time variability [17-36, 38-42] (See table 2 for specific study 
details). People with AD typically walked with reduced pace [17-20, 22-30, 32-36, 38, 40, 42] 
compared to controls, and were more impaired in severe AD [32, 36]. Reduced pace was also 
reported in AD compared to controls with low levels of white matter subcortical 
hyperintensities  but not compared to controls with high levels of subcortical hyperintensities 
[20].  
In AD, 18 studies assessed characteristics of rhythm, such as step, swing and stance 
time [18-20, 23-27, 29, 30, 32-35, 38, 39, 41]. The majority found impaired rhythm in AD 
compared to controls [18, 19, 23-25, 27, 30, 33-35]. One study found impaired rhythm with 
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increased dementia severity [32]. One study found impaired rhythm in AD compared to 
controls with low levels of subcortical hyperintensities but not high levels [20].  
In AD, 12 studies assessed features of variability, such as step velocity, step length 
and step width variability [17, 24-29, 31-33, 35, 39]. Results were inconsistent between AD 
and controls; five studies found increased variability in AD [17, 25, 27, 31, 33] while four did 
not [24, 26, 28, 35].  
In AD, only two studies assessed features of asymmetry such as step time, swing and stance 
asymmetry [26, 27]. Both compared AD to controls and MCI cohorts; no significant 
differences were found between any groups. In AD, nine studies assessed postural 
control of gait such as step width and step length asymmetry [17-19, 25, 33, 34, 40, 42]. 
Typically, there were no significant differences between AD and controls for postural 
control characteristics of gait [17-19, 33, 34, 40, 42, 43].  
Gait impairments in Lewy Body Dementia 
In LBD, three studies assessed gait. All studies assessed characteristics of pace [18, 37, 39] 
and generally found reduced pace compared to controls [18, 37]. Findings were also 
inconsistent between LBD and PD, with one study reporting reduced pace in LBD [39] and 
another study showing no group differences between PDD and PD [37]. No significant 
differences were found between subtypes of LBD [45]. In LBD, two studies assessed features 
of rhythm [18, 39] and found rhythm was impaired compared to controls [18]. One study 
reported impaired rhythm in LBD compared to PD but no significant differences between 
LBD subtypes [39]. In LBD, only one study assessed characteristics of variability [39]. It 
found no group differences between LBD and PD.  The same study assessed postural control 
characteristics of gait in LBD and found no significant differences between controls and DLB. 
Asymmetry was not assessed in LBD. 
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Gait impairments in Vascular Dementia 
One study assessed pace and postural control characteristics of gait in VaD [42]. It found 
reduced pace but no differences in postural control in VaD compared to both controls. 
Rhythm, variability and asymmetry were not assessed in VaD.  
3.6 Differences in gait between dementia subtypes and disease severity. 
People with AD demonstrated better pace compared to VaD [42]. In contrast, comparisons 
with LBD are inconsistent; one study found no difference in pace or rhythm between AD and 
DLB [18] whilst another reported reduced pace, impaired rhythm and increased variability in 
LBD compared to AD [39]. One study compared mild and moderate severity AD to mild and 
moderate severity unspecified non-AD dementia [25]; for both severity levels, non-AD 
dementia had reduced pace and a larger stride width (a feature of postural control). However, 
impaired rhythm was only found in the non-AD group in the moderate cohort and impaired 
variability only in the non-AD group in the mild cohort. No significant differences for 
postural control characteristics were found between AD and VaD or AD and DLB [18, 42]. 
Surprisingly, no significant differences were found in pace or rhythm between AD and PD 
[39]. 
Reduced pace was reported with increasing dementia severity. All four studies 
comparing dementia severity found reductions in pace in the moderate-to-severe AD groups 
compared to the milder groups [21, 31, 36, 41]. Results were inconsistent between AD and 
MCI; two studies reported slower pace in AD compared to MCI [27, 28] whilst two studies 
found no significant differences between these groups [22, 26]. No differences in 
characteristics of rhythm were found across dementia severity [22, 26, 41] and only one study 
reported impaired rhythm in AD compared to MCI [27]. Inconsistent results for variability 
were found between AD and MCI, with two studies showing increased variability in AD [26, 
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27] and two reporting no differences [22, 28]. One study found increased variability in 
moderate AD compared to mild AD [41] while another found increased variability in 
moderate and severe AD compared to controls; this was not found in mild AD [32]. Only one 
study found moderate AD had a larger stride width, a feature of postural control, compared to 
controls whereas mild AD did not [25]. No studies investigated asymmetry across dementia 
severity.  
Discussion 
This review aimed to summarize available data on gait differences in people with dementia 
compared to controls and identify distinct gait profiles in dementia subtypes. This review 
clarifies previous findings of gait impairment in dementia compared to controls, specifically 
attributing impairments to pace and rhythm domains. However, we extend previous literature 
by identifying that dementia subtypes differ from each other in characteristics of pace, rhythm 
and variability, although the number of studies comparing subtypes (Figure 3) and the range 
of gait characteristics described are limited. 
< Insert Figure 3 >  
Is gait in dementia distinct from normal aging?  
Our findings provide insight into significant impairments in gait in AD, VaD and LBD 
compared to non-cognitively impaired older adults that are consistent with our hypothesis. 
Reductions in pace was reported by the majority of studies, however it was also the most 
commonly assessed characteristic. Other discrete gait characteristics may have identified key 
discrete differences and need to be assessed in order to develop distinct patterns of gait for 
dementia subtypes [11]. Temporal gait characteristics (i.e. those in the rhythm domain) 
appeared more impaired in dementia and were dependent on disease stage. Impairments in 
variability are inconclusive, largely due to inconsistencies in the variables measured.  
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Are gait impairments distinctive between dementia subtypes? 
 The findings of this review support the qualitative literature reporting that gait is more 
impaired in non-AD dementia subtypes compared to AD and emphasizes differences across 
pace, rhythm and variability domains, which is somewhat consistent with our hypothesis [2]. 
Only four studies compared gait across subtypes, highlighting a significant gap in the literature. 
Interestingly, no differences were found between PD and AD in one study – however, trends 
indicated that PD walked slower with a mean velocity of 1.13 metres per second and mean 
stride length of 115.82 centimetres compared to 1.2 and 125.33 respectively [39]. One study 
reported differences across MCI subtypes, which may relate to different dementia subtypes. For 
example, when compared to controls, amnestic-MCI had slower pace, while non-amnestic-MCI 
had slower pace and impaired rhythm [25]. This may be due to pathological differences with 
important implications, as a-MCI usually develops into AD, while na-MCI progresses into non-
AD dementias, such as DLB or VaD [44]. Therefore, gait could act as an early marker to 
differentiate between dementia subtypes, however further work is needed to determine this.  
Do gait impairments across dementia subtypes relate to cognitive impairments and their 
underlying neural correlates? 
This review provides evidence for gait impairment in dementia subtypes reflecting 
cognitive impairments. Selective cognitive domains have been associated with discrete gait 
impairments which may reflect underlying pathology [12]. For example, characteristics of 
rhythm have been associated with memory, affected early in AD, while reduced pace and 
increased variability have been associated with impaired attention and executive function, 
affected early in LBD and VaD [11]. These cognitive impairments relate to the underlying 
neural correlates and pathological changes in different dementia subtypes. Our findings suggest 
that gait impairments may similarly reflect these differences. Dementias such as LBD have 
associated motor impairments due to disease pathology, such as neurodegeneration of the 
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substantia nigra, which produces key motor impairments of which gait asymmetry and postural 
control may be a feature. It is worth noting however, that despite these impairments, diagnosis 
in the early stages is still difficult.  Therefore while the differences in gait may not all be 
mediated by cognitive deficits and associated neural correlates, additional motor impairments 
may contribute to early differentiation.   
< Insert Figure 4 > 
An interesting question to ask is; do gait impairments reflect shared cognitive and 
pathological correlates consistent with different dementia subtypes? Alzheimer’s disease is 
associated with amnestic memory deficits predominantly due to amyloid deposition in the 
entorhinal cortex and hippocampus [45]. Atrophy of the hippocampus (involved in navigation 
and memory) is associated with decreased pace and variability  [46], with speculative links  
between rhythm and the hippocampus; temporal aspects of gait have been associated with 
memory [12].  Reduced pace and increased variability are associated with frontal lobe atrophy 
and white matter hyper-intensities affecting frontal subcortical circuits in both dementia and 
older adults – areas that mediate attention and executive function [46, 47]. Frontal white matter 
lesions are key characteristics of VaD [5] and frontal neuronal loss is associated with Lewy 
body disease, lending explanation to pace and variability deficits. There are also correlations 
between increases in gait impairment with dementia severity and reduced frontal cerebral blood 
flow becoming more widespread [32], suggesting gait impairment is reflective of ongoing 
neural changes in dementia. However, the majority of research associating gait with specific 
brain regions focuses on gait speed – further research needs to be completed before drawing 
any conclusions in this area.  
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Limitations of current research and recommendations for the future 
There are a number of discrepancies with the current research regarding quantitative gait 
assessment in dementia. Several additional studies using functional tasks (i.e. timed up and go) 
were identified but not included in this review, as they did not provide standardized measures 
of gait. This prevents comparison across studies and may be subject to confounding variables, 
such as impaired movement initiation. Of the studies that were included, distance walked, 
number of strides and steps, type of walk (i.e. continuous or intermittent) and gait analysis 
technique used (i.e. instrumented walkways, body worn sensors) varied. This limited 
interpretation when collating the results. Development of a standardized single-task gait 
protocol suitable for use in any clinic would be beneficial to aid generalizability of findings. 
This should include measuring at least 30 steps to assess variability characteristics [48]. 
Intermittent walks may be more suitable for dementia populations, particularly as the disease 
progresses – allowing for rest breaks as needed. Gait characteristics across studies also varied, 
with some studies limited to velocity and others assessing a wider range, such as stance time, 
step width, etc. Only two studies assessed features of asymmetry; this may be an oversight when 
considering dementias with notable asymmetric pathology, such as PDD, as asymmetric 
pathology may be reflected in gait outcomes. Studies should strive to assess a large range of 
spatial and temporal aspects of gait, to establish distinct gait profiles across dementia subtypes.  
 There was also a limited number of studies comparing dementia subtypes, as seen in 
Table 2. The majority focused on differences between AD and controls, with only five studies 
investigating non-AD dementias. Although non-AD dementias such as LBD and VaD have 
notable gait impairments as described in the qualitative literature [2], quantitative gait 
assessment is needed to tease out subtle differences that may support diagnosis. More studies 
comparing subtypes are necessary. There were also discrepancies across studies regarding 
severity measures – a number of rating scales, such as the MMSE or the CDR, were used to 
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establish stage of disease with inconsistent ratings determining disease stage. Studies were also 
restricted by small sample sizes and may not have provided a true picture of gait in dementia 
due to influence of outliers – studies should be adequately powered. Overall, the majority of 
studies were only of mediocre quality (see Supplementary Table 1 for more details). Therefore, 
we have provided key recommendations in Table 2 to guide future research.  
< Insert Table 2 > 
Clinical implications 
While gait impairments are recognisably present and often early markers of dementia 
subtypes such as VaD, PDD or DLB [2],  clinical recognition of gait deficits in AD is an 
emergent area of research. The National Institute of Neurological and Communicative Diseases 
and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
includes gait disturbances in their exclusion criteria for a diagnosis of AD [49, 50]. However 
the findings from this review and previous qualitative studies show that gait impairments are 
more common in AD compared to controls [2]. Qualitative literature suggests that gait 
impairments are not present in mild AD; however, quantitative gait analysis reveals subtle 
discrete deficits in mild AD that progressively worsen. Equally, while parkinsonism is a core 
feature of DLB according to the latest diagnostic criteria [51], specific gait impairments have 
not been described, and the revised DLB criteria suggests that at least one clinical marker and 
a biomarker suggestive of Lewy body disease are necessary for early diagnosis. Although 
limited, the current evidence suggests that dementia subtypes have distinctive patterns of gait 
impairment. While more research is necessary in order to establish unique gait profiles in 
dementia subtypes, the end-result could complement current diagnostic criteria and show 
potential utility as a biomarker. Similar to acknowledging the specific cognitive domains 
impaired early in disease onset (e.g. episodic memory in AD), specific gait domains may also 
be impaired early (e.g. rhythm in AD). Changes in gait are also found prior to onset of cognitive 
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decline; therefore, gait analysis at early intervals could contribute to early diagnosis of 
dementia. With advancing technology, quantitative gait analysis techniques are becoming 
smaller, portable and more cost-effective and could prove a useful addition to a clinician’s 
toolbox.  
Conclusion 
Gait is impaired in dementia compared to cognitively intact older adults. Dementia 
subtypes may have discrete gait profiles but more research is necessary to establish these. Use 
of standardized protocols and assessment of a comprehensive range of spatiotemporal gait 
characteristics are necessary when studying gait in dementia and its subtypes. Future research 
should endeavor to establish quantitative gait analysis as a cost-effective and easily applicable 
clinical biomarker for dementia. 
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Table 1: Descriptive information and methodology of all cross-sectional studies 
Study Participant 
Characteristics 
Diagnostic Criteria Severity Rating Gait analysis tool 
(distance) 
Gait parameters 
measured (units) 
Main study findings 
Merory, et al. [18] 10 AD; 8M/2F, age: 76±6, 
MMSE: 28.7±1.2, UPDRS: 
2.7±4.2 
10 DLB; 8M/2F; age: 
73±5, MMSE: 23.5±4, 
UPDRS: 27.1±9.4 
10 Controls; 8M/2F, age: 
72±7, MMSE: 28.7±1.2 
AD: NINCDS-ADRDA 
DLB: McKeith 
Not specified GAITRite (8.3m x 0.89m) Velocity (not specified) 
Cadence (not specified) 
Stride length (not 
specified) 
Step width (not specified) 
Double support time (not 
specified) 
AD and DLB: slower 
velocity, shorter stride 
length and increased 
double support time 
compared to controls. 
No significant differences 
between AD and DLB 
[17] Groups split by subcortical 
hyperintensity severity: (+) 
high severity, (-) low 
severity 
42 AD; 60%F, age: 74±8, 
MMSE: 25±3, UPDRS: 
7±7. 
21 AD -; 68%F, age: 71±9, 
MMSE: 24±3, UPDRS 
±3±3 
21 AD+; 52%F, age: 77±6, 
MMSE: 25±2, UPDRS: 
11±9 
33 Controls; 47%, age: 
73±8, MMSE: 29±1, 
UPDRS, 3±4 
18 Controls -; 44%F, age: 
69±7, MMSE: 29±1, 
UPDRS: 1±3 
15 Controls +; 53%F, 
76±7, MMSE: 28±1.3, 
UPDRS: 3±3 
NINCDS-ADRDA – 
probable AD 
MMSE ≥ 20. 
Dementia Rating Scale 
GAITRite (2 x 12ft) 
 
Velocity (cm/s) 
Stride Length (cm) 
Cadence (Steps/min) 
Step width (cm) 
Controls -: faster velocity 
compared to controls +, 
AD – and AD +. Stride 
length longer and cadence 
higher compared to AD – 
and AD + 
Ries, et al. [21] 20 mild-moderate AD; 
60%F, age: 81.05±9.48, 
MMSE: 17.4±4.5 
31 moderate-severe AD; 
70.7%F, age: 80.48±8.43, 
MMSE: 10.20±8.83 
Not specified FAST 4/5: mild – moderate 
AD 
FAST 6/7: moderate – 
severe AD 
GAITRite (15ft) Gait speed (cm/s) Moderate-severe AD had a 
slower gait speed on the 
GAITRite.  
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Gras, et al. [23] 13 AD; 10M/3F, age: 
72.9±4.7, MMSE: 24.8±2.6 
13 Controls; 10M/3F, age: 
72.6±4.6, MMSE: 29±1 
NINCDS-ADRDA CDR 0.5: very mild AD GAITRite (4.88m) Velocity (m/s) 
Stance time (s) 
Step length (m) 
 
AD: slower velocity, 
longer stance time, shorter 
step length compared to 
controls.  
Visser [24] 11 AD; 2M/9F, age: 
78.8±2.5. 
11 Controls; 2M/9F, age: 
78.3±2.6 
Not specified Set Test (Isaacs & Akhtar): 
severe dementia  - < 10, 
moderate dementia – 10-20 
Specially designed 
walkway with sensors (6m) 
Speed (m/s) 
Step frequency (steps/sec) 
Step length (cm) 
Double support ratio (%) 
CV step length (%) 
AD: slower walking speed, 
shorter step length, lower 
step frequency and 
increased double support 
ratio compared to controls 
 
Gillain, et al. [26] 6 AD; 9%M, 9%F (overall 
sample), age: 73.66, 
MMSE: 22.83±2.14, 
education: 9.33±3.78 
14 MCI; 21%M, 21%F, 
age: 72.85, MMSE: 
26.71±1.68, education: 
13.64±3.3 
14 Controls; 19%M, 21%F, 
age: 75.53, MMSE: 
28.21±1.58, education: 
13.71±3.73 
AD: NINCDS-ADRDA 
MCI: Confirmed isolated 
cognitive disorder that 
doesn’t affect activities of 
daily living 
CDR 0.5: MCI 
CDR 1: AD 
MMSE ≥ 24 – MCI 
MMSE ≥ 20 - AD 
Tri-axial accelerometer 
(40m x 2 times) 
 
Gait speed (m/s) 
Stride frequency (hz) 
Stride length (m) 
Regularity (dimensionless) 
Symmetry (dimensionless) 
Stops 
AD: Slower speed and 
shorter stride length 
compared to controls. 
AD had reduced regularity 
compared to MCI. MCI 
had reduced stride 
frequency compared to 
controls. 
Maquet, et al. [27] 6 AD; 3M/3F, age: 74±4 
14 MCI; 7M/7F, age: 73±4 
14 Controls; 7M/7F, age: 
74±5 
AD: NINCDS-ADRDA 
a-MCI: Pearson et al, 2001 
na-MCI: Winblad et al, 
2004 
CDR 0.5: MCI 
CDR 1: AD 
MMSE 24≥ - MCI 
MMSE 20≥ - AD 
Accelerometer (45m x 
2times)  
Walking speed (m/s) 
Stride frequency (hz) 
Stride length (m) 
Symmetry (au) 
Regularity (au) 
Stops (au) 
AD: slower walking speed, 
lower stride frequency, 
shorter stride length and 
decreased regularity 
compared to controls.  
AD: slower walking speed, 
lower stride frequency, 
shorter stride length and 
decreased regularity 
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compared to MCI. 
MCI: reduced stride 
frequency compared to 
controls. 
Choi, et al. [28] 10 AD; 4M/6F, age: 
77.2±6.84 
7 MCI; 4M/3F, age: 
72.9±6.28 
6 Controls; 4M/2F, age: 
71.6±5.78 
Not specified Not specified Tri-axial accelerometer 
(100m) 
Stride time (not defined) 
CV stride time 
Detrended fluctuation 
analysis 
Spectral analysis (LF/HF 
ratio) 
AD: increased CV stride 
time compared to controls. 
AD: increased CV stride 
time compared to MCI. 
MCI: slower stride time, 
increased CV stride time 
and increased LF/HF ratio 
compared to controls. 
Lamoth, et al. [29] 13 AD; 4M/9F, age: 
82.62±4.29, MMSE: 
18±3.54 
13 Controls; 6M/7F, age: 
79.38±5.55, MMSE: 
28.23±1.09 
Criteria of Alzheimer’s 
Association 
MMSE < 23 Tri-axial accelerometer Speed (m/sec) 
Stride frequency 
(stride/sec) 
Stride time (sec) 
CV stride time (%) 
Phase variability index (%) 
Stride-to-stride variability 
(%) 
No significant differences 
found between groups 
Nakamura, et al. [31] 10 mild AD fallers; 2M/8F, 
age: 75.4±2.5, MMSE: 
17.8±2.1, disease duration: 
2.9±0.7 
40 mild AD non-fallers; 
9M/31F, age: 74.6±2.7, 
MMSE: 18±1.8, disease 
duration: 3.1±0.5 
18 moderate AD fallers; 
NINCDS-ADRDA – 
probable AD 
DSM-III-R 
MMSE 
CDR 1: Mild A 
CDR 2: Moderate AD 
Motion capture analysis 
system (10 strides) 
Speed 
Stride length 
CV stride length (%) 
Moderate AD had a slower 
walking speed, shorter 
stride length and increased 
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5M/13F, age: 74.8±2.3, 
MMSE: 11.3±2.6, disease 
duration: 6.0±0.8 
29 moderate AD non-
fallers: 8M/21F, age: 76±3, 
MMSE: 12.2±2.1, disease 
duration: 5.8±1 
CV stride length compared 
to mild AD. 
Nakamura, et al. [32] 45 AD; 13M/32F, age: 76.8 
(73-82) – Split by severity 
levels. 
15 CDR1; 5M/10F, age: 
75.9±3.6, MMSE: 
18.6±1.7, disease duration: 
2.2±1.8 
15 CDR2; 4M/11F, age: 
77.5±4.0, MMSE: 
11.4±2.6, disease duration: 
4.3±1.6 
15 CDR3; 4M/11F, age: 
78.1±3.2, MMSE: 6.8±2.4, 
disease duration: 7.0±2.1 
15 Controls; 5M/10F, age: 
77.1±3.4, MMSE: 27.4±1.3 
DSM-III-R criteria for 
probable AD. 
NINCDS-ADRDA 
MMSE 
CDR1: Mild  
CDR2: Moderate 
CDR3: Severe 
Motion capture analysis 
system (10m) 
Walking speed (m/s) 
Stride length (m) 
Double support time (s) 
CV stride length (%) 
AD -Moderate and severe: 
slower walking speed, 
shorter stride length, 
increased double support 
time, increased CV stride 
length  compared to 
controls. 
AD – mild: did not differ 
from controls. 
Statistical comparisons 
between dementia severity 
groups not reported but 
trend implies that gait 
impairments worsen with 
progression of dementia. 
Barbieri, et al. [33] 15 AD; age: 78.33±5.23, 
MMSE: 17.73±3.93. 
15 Controls: age: 77.44± 
6.19, MMSE: 27.4±2.38. 
Not specified CDR 
Neuropsychiatric inventory 
Motion capture analysis 
system (8m) 
Stride length (cm) 
Step width (cm) 
Stride duration (s) 
Stride velocity (cm/s) 
Double support duration 
(%) 
AD: shorter stride length, 
double-support duration, 
longer stride duration, 
slower stride velocity, 
increased CV stride length, 
increased CV double 
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CV stride length (%) 
CV step width (%) 
CV stride duration (%) 
CV stride velocity (%) 
CV double support 
duration (%) 
support time and increased 
CV stride duration 
compared to controls.  
Simieli, et al. [34] 18 AD; 4M/15F, age: 
78.33±5.23 
15 Controls; age: 
77.44±6.19 
DSM-IV-TR and 
International Disease Code 
CDR 1 and CDR 2 
Neuropsychiatric inventory 
Motion capture analysis 
system (8m) 
Stride length (cm) 
Step width (cm) 
Single support duration (s) 
Double support time (s) 
Stride duration (s) 
Stride velocity (cm/s) 
AD: shorter stride length, 
shorter stride width,  
slower stride velocity, 
increased single support 
duration, increased double 
support time and longer 
stride duration compared to 
controls 
Lin, et al. [35] 10 AD; 2M/8F, age: 
74±8.6, MMSE: 17.7±4.1. 
10 Controls, 2M/8F, age: 
73.8±6.1, MMSE: 29.4±0.7 
Criteria not specified.  
 
CDR: 0.8±0.3 - mild Motion capture analysis 
system (8m) 
Velocity (leg length/sec) 
Cadence (steps/min) 
Stride length (leg length) 
CV stride length (%) 
Stride time (s) 
CV stride time (%) 
AD: slower velocity, 
decreased cadence and 
longer stride time 
compared to controls.  
Goldman, et al. [36] 40 very mild AD; 
19M/21F, age: 71.98±7.51, 
education: 13.72±3.36 
20 mild AD; 9M/11F, age: 
73.68±7.82, education: 
12.05±3.63 
43 Controls; 21M/22F, age: 
73.22±7.70, education: 
14.44±3.26 
NINCDS-ADRDA CDR 0.5: very mild 
CDR 1: mild 
Electric contact footpads 
with pressure-activated 
foot-switches (10m) 
Velocity (distance/time) Mild AD: slower velocity 
compared to controls. 
Very mild AD: did not 
differ from controls 
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Mild AD: slower velocity 
compared to very mild AD. 
Goldman, et al. [37] 22 PDD; 19M/3F, age: 
71.6±7.8, education: 
13.7±3.7 
58 PD; 42M/16F, age: 
69.7±6.0, education: 
14.8±3.1 
43 Controls; 21M/22F, age: 
73.2±7.7, education: 
14.4±3.3 
Not specified CDR 0.5: Questionable 
dementia 
Electric contact footpads 
with pressure-activated 
foot-switches (10m) 
Velocity (cm/s) PDD: slower velocity 
compared to controls but 
did not differ from PD. 
Nadkarni, et al. [19] 40 AD; 55%F, age: 74±8, 
MMSE: 25±3, UPDRS: 
7±8. 
34 Controls; 45F, age: 
73±8, MMSE: 29±1, 
UPDRS: 2±4 
NINCDS-ADRDA MMSE 
Dementia Rating Scale 
GAITRite (2 x 12ft). 
Footswitches with 
motorised treadmill.  
 
GAITRite: 
Velocity (cm/s) 
Cadence (steps/min) 
Stride length (cm) 
Cycle time (s) 
Stride width (cm) 
Double support time (s) 
Treadmill: 
Belt speed (cm/s) 
Cadence (steps/min) 
Cycle time (s) 
Double support time (s) 
CV cycle time (%) 
CV double support time 
(%) 
GAITRite: AD had a 
slower velocity, decreased 
cadence, shorter stride 
length, longer cycle time 
and longer double support 
time than controls.  
Treadmill: AD had a 
slower belt speed and 
decreased cadence than 
controls compared to 
controls. 
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Nadkarni, et al. [20] 24 AD; 60%F, age: 75±9, 
MMSE: 25±3, UPDRS: 
6±7 
20 Controls; 47%F, age: 
72±8, MMSE: 29±1, 
UPDRS: 3±4 
NINCDS-ADRDA – 
probable AD 
MMSE 
Mattis Dementia Rating 
Scale 
Footswitches on a 
motorised treadmill. 
 
Overground gait speed 
(m/s) 
Self-selected treadmill 
walking speed (m/s) 
Cadence (not defined) 
Cycle time (not defined) 
Double support time (not 
defined) 
AD: slower overground 
gait and slower self-
selected treadmill walking 
speed compared to 
controls.  
Fritz, et al. [39] 21 AD; 13M/8F, age: 
75.05±4.96, MMSE: 
22.43±4.25, education: 
14.67±2.13, UPDRS: 
3.9±3.62 
21 LBD; 13M/8F, age: 
73.95±4.78, MMSE: 
22.57±3.57, education: 
15.57±2.58, UPDRS: 
25.95±5.82 
LBD group split into 
subtypes DLB and PDD. 
11 DLB; 6M/5F, age: 
73.7±4.59, MMSE: 
24.45±4.46, education: 
15.54±2.38, UPDRS: 
24.45±6.3 
10 PDD; 7M/3F, age: 
74.2±5.16, MMSE: 
27.6±2.51, education: 
15.6±2.91, UPDRS: 
27.6±5.04 
21 PD; 13M/8F, age: 
72.38±4.72, MMSE: 
27.81±1.36, education: 
14.86±2.31, UPDRS: 
25.52±5.89 
AD: NINCDS-ADRDA – 
probable 
DLB: McKeith 
PDD: Emre 
Not defined GAITRite 
 
Velocity (m/s) 
Stride length (m) 
Swing (%) 
Swing time (s) 
Stance(%) 
Double support (%) 
CV step time (%) 
CV step length (%) 
CV stride length (%) 
CV swing time (%) 
CV stance time (%) 
CV double support time 
(%) 
 
LBD: slower velocity, 
shorter stride length, 
increased stance time, 
increased double support 
time, decreased CV double 
support time compared to 
PD. 
AD: No differences found 
between AD and PD. CV 
measures were not 
investigated between AD 
and PD.  
LBD vs AD: slower 
velocity, shorter stride 
length, decreased swing, 
increased stance time, 
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increased double support 
time, increased CV step 
time, increased CV step 
length, increased stride 
length, CV swing time and 
took longer to complete 
TUG compared to AD.  
DLB vs PDD: No 
significant differences 
between groups – CV 
differences not reported 
between groups. 
Suttanon, et al. [40] 25 AD; 9M/16F, age: 81 
(78.4-83.5), MMSE: 21.1 
(19.2-23) 
25 Controls; 9M/16F, age: 
80.4 (78-82.7), MMSE: 
29.2 (28.5-29.8) 
Not specified MMSE ≥ 10 – mild-
moderate dementia 
Forceplate (360cm) 
 
Step width (cm) 
Step length (cm) 
Walking speed (m/s) 
AD: slower walking speed 
and shorter step length 
compared to controls.  
Coelho, et al. [41] 12 Mild AD; age: 75.7±6.8, 
MMSE: 22±2.2, education: 
5.5±3.0. 
11 Moderate AD; age: 
80.1±7.5, MMSE: 
16.2±2.2, education: 
3.5±1.1 
DSM IV - TR CDR 1: Mild 
CDR 2: Moderate 
 
Digital camera with passive 
marker (8m x 1.4m). 
 
Stride length (m) 
Stride speed (m/s) 
Cadence (strides/sec) 
 
Moderate AD had a shorter 
stride length and slower 
stride speed compared to 
mild AD.  
 
Tanaka, et al. [42] 15 AD; 15F, age: 79.8±4.6 
15 VaD; 15F, age: 
80.3±4.4 
15 Controls; 15F, age: 
78.3±6.9 
DSM IIIR MMSE, CDR 10m walkway 3 times. 
Measurement of gait 
parameters not specified. 
Walking velocity (m/s) 
Step length (mm) 
Step width (mm) 
VaD and AD: slower 
velocity and shorter step 
length compared to 
controls 
VaD: slower velocity and 
shorter step length 
compared to AD. 
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 10 AD; 7M/3F, age: 
77.6±5.5, MMSE: 18.9±3.9 
10 Controls; 7M/3F, age: 
72.4±6.5, MMSE: 28.4±1.7 
NINCDS-ADRDA Not specified GAITRite (8m) Speed (m/s)  
Stride length (m) 
CV stride length (%) 
Step width (cm) 
CV step width (%) 
AD: slower speed, shorter 
stride length and increased 
CV stride length compared 
to controls. 
Allali, et al. [25] 196 mild AD; 134F, age: 
82.5±5.1 
177 moderate AD; 121F, 
age: 83.9±5.6 
126 mild non-AD; 71F, 
age: 81.9±5.1 
91 moderate non-AD; 52F, 
age: 83.3±5.2 
108 a-MCI; 40F, age: 
76.7±7.9 
286 na-MCI; 134F, age: 
75.5±6.6 
735 Controls; 374F, age: 
73.9±6.3 
Dementia subtypes: DSM-
IV apart from TASCOG 
cohort (self-report, medical 
review, cognitive testing, 
clinical interview) 
MCI subtypes: spontaneous 
cognitive complaints and 
objective impairment in 
memory/multiple domains 
Mild dementia: CDR 1, 
MMSE ≥20 
Moderate: CDR 2, MMSE 
19-10 
GAITRite (ranging from 
4.6m to 7.9m) 
Walking speed (cm/s) 
Stride length (cm) 
Stride time (ms) 
Swing time (ms) 
Stance time (ms) 
Single support time (ms) 
Double support time (ms) 
Stride width (cm) 
Stride velocity (m/s) 
CV stride length (%) 
CV stride time (%) 
CV swing time (%) 
CV stance time (%) 
CV single support time (%) 
CV double support time 
(%) 
CV stride width (%) 
CV stride velocity (%) 
All dementia groups 
(mild/moderate AD and 
non-AD) had slower 
walking speed, shorter 
stride length, increased CV 
stride length, longer stride 
time, increased CV stride 
time, longer stance time, 
increased CV stance time, 
increased CV single 
support time, longer double 
support time, increased CV 
double support time, 
slower stride velocity and 
increased CV stride 
velocity compared to 
controls. 
All dementia groups except 
mild AD demonstrated 
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larger stride width and 
reduced CV stride width 
variability compared to 
controls.  
Only mild AD showed 
increased single support 
time compared to controls.  
Mild dementia: OD had 
increased CV stride length, 
larger stride width, reduced 
CV stride width and 
increased CV stride 
velocity compared to AD. 
Moderate dementia: OD 
had slower walking speed, 
shorter stride length, longer 
stance time, increased CV 
stance time, larger stride 
width, and slower stride 
velocity compared to AD. 
a-MCI: slower walking 
speed, increased CV stance 
time, slower stride velocity 
and increased CV stride 
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velocity compared to 
controls. 
na-MCI: slower walking 
speed, shorter stride length, 
increased CV stride length, 
slower stride time, 
increased CV stride time, 
longer stance time, 
increased CV stance time, 
increased CV single 
support time, longer double 
support time, increased CV 
double support time, 
slower stride velocity and 
increased CV stride 
velocity compared to 
controls.  
Muir, et al. [22] 23 AD; 14F, age: 77.5±5, 
MMSE: 24.2±2.3, 
education: 12.3±3.4 
29 MCI; 17F, age: 
73.6±6.2, MMSE: 27.5±1.9 
22 Controls; 19F, age: 
71±5, MMSE: 29.5±0.6, 
education: 13.4±3.1 
AD: NINCDS-ADRDA 
MCI: Subjective memory 
complaint, report of 
cognitive deterioration, 
objective memory 
impairment in cognitive 
tests with lack of functional 
impairment and absence of 
clinical dementia 
CDR 0.5: MCI 
MMSE 20≥ - AD 
GAITRite (600cm x 64cm) Gait velocity (cm/s) 
Stride time (ms) 
CV stride time (%) 
No significant differences 
between groups 
Hsu, et al. [30] 21 AD; 10M/11F, age: 
61.48±4.85, MMSE: 
23±3.23 
50 Controls; 20M/30F, age: 
59.86±4.62, MMSE: 
28.38±1.55 
Not specified Not specified Wearable device with tri-
axial accelerometer, bi-
axial gyroscope, uni-axial 
gyroscope, microcontroller 
and micro SD flash card 
No. of strides (count) 
Walking time (s) 
Stride length (m) 
AD: higher number of 
strides, slower walking 
time, shorter stride length, 
Gait analysis in dementia subtypes 
 
32 
 
Stride frequency (hz) 
Stride speed (m/s) 
Stride cadence (stride/min) 
Stride time (s) 
Stance time (s) 
CV stride time (%) 
CV stance time (%) 
CV swing time (%) 
Stance period (%) 
Swing time (%) 
CV stance period (%) 
CV swing period (%) 
slower stride speed, longer 
stance time, longer stance 
period, shorter swing 
period, increased CV 
stance period and increased 
CV swing period compared 
to controls.  
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Table 2: Recommendations for future research  
Key recommendations for future research  
 Development of a standardized single-task gait protocol.  
 Adopting a standardized framework to inform selection of gait characteristics – such 
as models suggested by Hollman, et al. [14], Lord, et al. [16], Verghese, et al. [52] 
 More studies are needed to compare gait across the most common subtypes, i.e. AD, 
DLB, PDD and VaD.  
 Follow recommended diagnostic criteria for dementia to ensure accuracy of 
diagnosis in order to compare dementia sub-types (Dubois, et al. [49], McKhann, et 
al. [50], McKeith, et al. [51], Emre, et al. [53]).  
 Adherence to guidelines regarding measures for assessing stage of dementia [54, 55] 
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Figure 1: Lord, et al. [16]’s model of gait for older adults. Gait domains include pace, 
rhythm, variability, asymmetry and postural control. 
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Figure 2: Flowchart of search strategy and extraction of eligible studies.  
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Figure 3: Heat map detailing number of studies comparing groups. AD = Alzheimer’s 
Disease, VaD = Vascular dementia, DLB = Dementia with Lewy bodies, PDD = Parkinson’s 
disease with dementia, LBD = Lewy body dementia, OD = unspecified non-AD dementias, 
MCI = mild cognitive impairment, PD = Parkinson’s disease.  
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Figure 4: Associations between dementia subtypes and gait implied by the current literature, 
using Lord, et al. [16]’s as a framework to interpret results.  
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Supplementary Materials 
Supplementary Table 1: Quality assessment of all studies included in this review, as conducted by reviewers R.M.A and J.W. 
 
Study Was the 
research 
question or 
objective in 
this paper 
clearly stated? 
Was the study 
population 
clearly 
specified and 
defined? 
Were 
withdrawals 
reported and 
explained? 
Were inclusion 
and exclusion 
criteria for 
participants 
defined and 
determined 
prior to the 
study onset?  
Was a sample 
size 
justification, 
power 
description, or 
variance and 
effect estimates 
provided? 
Were the 
outcome 
measures 
(dependent 
variables) 
clearly defined, 
valid, reliable, 
and 
implemented 
consistently 
across all study 
participants? 
Were clinical 
diagnostic 
criteria and 
severity 
ratings for 
dementia 
reported and 
adhered to? 
Were key 
potential 
confounding 
variables 
measured and 
adjusted 
statistically for 
their impact on 
the 
outcome(s)? 
Quality 
Assessment: 
Reviewer 1 
(R.M.A.) 
Quality 
Assessment: 
Reviewer 2 
(J.W.) 
Visser [1] Yes No Yes No No No No No Poor (2/8) Poor (2/8) 
Tanaka, et al. 
[2] 
Yes Yes n/a No No No R.M.A Yes 
 
No Poor (3/8) Poor (2/8) 
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J.W.  No 
Nakamura, et 
al. [3] 
Yes Yes Yes Yes No Yes Yes No Mediocre (6/8) Mediocre (6/8) 
Nakamura, et 
al. [4] 
Yes Yes n/a Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
Goldman, et al. 
[5] 
Yes Yes No Yes No Yes R.M.A  No 
 
J.W. Yes 
Yes Mediocre (5/8) Mediocre (6/8) 
Goldman, et al. 
[6] 
No Yes R.M.A Yes 
 
J.W. No 
Yes No Yes No Yes Mediocre (5/8) Mediocre (4/8) 
Webster, et al. 
[7] 
Yes Yes Yes Yes No Yes Yes No Mediocre (6/8) Mediocre (6/8) 
Merory, et al. 
[8] 
Yes Yes Yes Yes No Yes Yes No Mediocre (6/8) Mediocre (6/8) 
Gillain, et al. 
[9] 
Yes Yes n/a Yes Yes Yes Yes No Mediocre (6/8) Mediocre (6/8) 
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Nadkarni, et al. 
[10] 
Yes Yes n/a Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
Nadkarni, et al. 
[11] 
Yes Yes n/a Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
Ries, et al. [12] Yes Yes Yes Yes No Yes R.M.A.   No 
 
J.W.  Yes 
No Mediocre (5/8) Mediocre (6/8) 
Maquet, et al. 
[13] 
Yes Yes n/a Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
Choi, et al. [14] Yes No n/a No No Yes No No Poor (2/8) Poor (2/8) 
Lamoth, et al. 
[15] 
Yes Yes n/a Yes No Yes Yes No Mediocre (5/8) Mediocre (5/8) 
Coelho, et al. 
[16] 
Yes No R.M.A.  Yes 
 
J.W.  No 
R.M.A.  No 
 
J.W.  Yes 
No Yes Yes No Mediocre (4/8) Mediocre (4/8) 
Muir, et al. [17] Yes Yes n/a Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
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Nadkarni, et al. 
[18] 
Yes Yes n/a Yes No No Yes Yes Mediocre (5/8) Mediocre (5/8) 
Suttanon, et al. 
[19] 
Yes Yes n/a Yes R.M.A.  No 
 
J.W.  Yes 
Yes No Yes Mediocre (5/8) Mediocre (6/8) 
Hsu, et al. [20] No Yes n/a Yes No Yes No No Poor (3/8) Poor (3/8) 
Barbieri, et al. 
[21] 
Yes No R.M.A.  Yes 
 
J.W.  n/a 
No No Yes No Yes Mediocre (4/8) Poor (3/8) 
Gras, et al. [22] Yes No n/a No No Yes No Yes Poor (3/8) Poor (3/8) 
Simieli, et al. 
[23] 
Yes Yes No No Yes Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
Allali, et al. 
[24] 
Yes Yes Yes Yes No No No Yes Mediocre (4/8) Mediocre (5/8) 
Fritz, et al. [25] Yes Yes No Yes No Yes Yes Yes Mediocre (6/8) Mediocre (6/8) 
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Lin, et al. [26] Yes Yes n/a No No Yes No Yes Mediocre (4/8) Mediocre (4/8) 
         Total: 
0 Good 
21 Mediocre 
5 Poor 
Total: 
0 Good 
20 Mediocre 
6 Poor 
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Supplementary Table 2: Definitions for commonly described characteristics of gait.   
Gait Terms: Definition: 
Step Every time a leg goes forward during walking 
Step Length Distance between the heel of a trailing foot and the heel of the leading 
foot.  
Stride When both a left and right footstep have been taken 
Stride time The time it takes to make a stride – also referred to as gait cycle 
duration. 
Stance When the foot is on the ground during walking – also referred to as 
single support duration.  
Swing When the foot is not on the ground during walking 
Double Support When both feet are on the ground during walking.  
Velocity Refers to the speed of walking – calculated as distance/time 
Cadence Number of steps per defined time measure (e.g. steps per minute) 
Step width Mediolateral distance between heels during double support 
Pace How fast or slow someone walks 
Rhythm Refers to temporal characteristics of walking, such as swing, stance 
and step time. 
Variability Changes in spatio-temporal parameters of gait, usually regarding step-
to-step fluctuations. E.g. how much step length changes from one step 
to the next.  
Asymmetry The ratio between right and left steps 
Postural control Referring to characteristics contributing to keeping individuals upright 
during walking.  
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